Biotechnology Research · Hamburg
Topas Therapeutics is a clinical-stage biotechnology company transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology. Our antigen-coupled nanoparticle platform harnesses the tolerogenic power of the liver to treat autoimmune diseases. Our proprietary Topas Particles Conjugates target liver sinusoidal endothelial cells, a specific type of antigen-presenting cells highly effective at inducing T cell tolerance. With a technology adjustable to a broad spectrum of disease-relevant antigens, we have established a growing and advanced clinical pipeline to induce systemic tolerance. To learn more visit https://topas-therapeutics.com/